Free Trial
NASDAQ:CLBT

Cellebrite DI Q3 2026 Earnings Date & Estimates

Cellebrite DI logo
$11.38 +0.55 (+5.08%)
Closing price 04:00 PM Eastern
Extended Trading
$11.50 +0.12 (+1.05%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellebrite DI is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for 5:00 PM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
5:00 PM ET

What Analysts Expect from Cellebrite DI in Q3 2026

Cellebrite DI is expected to post earnings of $0.17 per share on revenue of $145.89 million. In the same quarter a year earlier Cellebrite DI reported $0.08 per share on revenue of $126.03 million. Cellebrite DI last reported on February 11, 2026, posting $0.14 per share and matching the $0.14 consensus estimate. Cellebrite DI has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.17
Expected Revenue
$145.89 million
Prior-Year EPS
$0.08
Prior-Year Revenue
$126.03 million
Expected EPS Growth
+112.5%
Expected Revenue Growth
+15.8%

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$0.14 (Met Expectations)
Last Quarter Revenue
$128.82 million
EPS Beat Rate
5 of last 8 quarters

Cellebrite DI Q3 2026 Earnings FAQ

Cellebrite DI (NASDAQ:CLBT) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Cellebrite DI's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cellebrite DI to post earnings of $0.17 per share for Q3 2026.

The consensus revenue estimate for Cellebrite DI is $145.89 million for Q3 2026.

Cellebrite DI Earnings Headlines

Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
See More Cellebrite DI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellebrite DI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellebrite DI and other key companies, straight to your email.

About Cellebrite DI

Cellebrite DI (NASDAQ:CLBT) is a digital intelligence company that develops technology for collecting, managing and analyzing digital evidence. Its solutions are designed to help law enforcement agencies, public safety organizations, government bodies and enterprises investigate activity involving mobile devices, computers, cloud services and other digital sources.

The company’s product portfolio includes tools for mobile-device extraction and digital forensics, investigative analytics, evidence management and collaboration. Its offerings include the UFED platform, Inseyets digital forensics solutions, Pathfinder investigative analytics and Guardian, a cloud-based platform intended to support the secure management and sharing of digital evidence and investigative workflows.

Founded in Israel, Cellebrite serves customers in numerous countries through a global sales and support network. The company became publicly traded on the Nasdaq under the symbol CLBT in 2021 following its business combination with special purpose acquisition company TWC Tech Holdings II Corp. Cellebrite’s customers primarily include government and law enforcement organizations, although it also provides solutions for corporate and other investigative users.

View Cellebrite DI Profile